Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 15;22(11):111.
doi: 10.1007/s11912-020-00973-0.

The Changing Landscape of Lymphoma Associated with HIV Infection

Kai Hübel  1
Affiliations
Review

The Changing Landscape of Lymphoma Associated with HIV Infection

Kai Hübel. Curr Oncol Rep. .

Erratum in

Abstract

Purpose of review: Cancer remains a major cause of morbidity and mortality in HIV-infected individuals, with aggressive non-Hodgkin's lymphoma as the most frequent one. However, the introduction of modern antiretroviral therapy (ART) drastically improved treatment options and prognosis in HIV-associated lymphomas. This review summarized the current treatment landscape and future challenges in HIV-positive patients with non-Hodgkin's and Hodgkin's lymphoma.

Recent findings: Selecting the appropriate therapy for the individual patient, diffuse-large B cell lymphoma, Burkitt's lymphoma, and Hodgkin's disease may be curable diseases. In contrast, the prognosis of plasmablastic lymphoma and primary effusion lymphoma remain poor. New treatment approaches, as targeted therapies or CAR T cell therapy, may broaden the therapeutic armamentarium. The continuous application of ART is mandatory for successful treatment. The choice of lymphoma therapy may follow the recommendations for HIV-negative patients, but prospective trials in HIV-lymphoma are needed.

Keywords: Antiretroviral therapy; HIV lymphoma; Pathogenesis; Risk factors; Treatment.

PubMed Disclaimer

Conflict of interest statement

The author declares that there is no conflict of interest.

References

    1. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, Georget A, Aouba A, Rosenthal E, May T, Chauveau M, Diallo B, Costagliola D, Chene G, ANRS EN20 Mortalité 2010 Study Group Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28(8):1181–1191. doi: 10.1097/QAD.0000000000000222. - DOI - PubMed
    1. Schneider E, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. MMWR Recomm Rep. 2008;57(RR-10):1–12. - PubMed
    1. Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M, Collaboration of Observational HIV Epidemiological Research Europe HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. Blood. 2011;117(23):6100–6108. doi: 10.1182/blood-2010-08-301531. - DOI - PubMed
    1. Said J, et al. et al. In: Lymphomas associated with HIV infection. In: WHO classification of tumors of haematopoietic and lymphoid tissues. 4. Swerdlow SH, et al.et al., editors. Lyon: IARC Press; 2017. pp. 449–452.
    1. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213–1224. doi: 10.1182/blood-2008-09-180315. - DOI - PubMed

MeSH terms

Substances